Actively Recruiting
A Cell-free tsRNA Signature for Early Detection of Hepatocellular Carcinoma
Led by City of Hope Medical Center · Updated on 2025-12-10
600
Participants Needed
1
Research Sites
74 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Hepatocellular carcinoma (HCC) is often diagnosed at an advanced stage, and early detection is critical for improving patient outcomes. Despite this, reliable non-invasive biomarkers for early-stage HCC are limited. This study seeks to develop a cell-free tsRNA (cf-tsRNA)-based liquid biopsy assay for accurate detection of early-stage HCC.
CONDITIONS
Official Title
A Cell-free tsRNA Signature for Early Detection of Hepatocellular Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- A histologically confirmed diagnosis of hepatocellular carcinoma.
- Received standard diagnostic and staging procedures as per local guidelines
- Availability of at least one blood-derived sample, drawn before receiving any curative-intent treatment
You will not qualify if you...
- Lack of or inability to provide informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
City of Hope Medical Center
Duarte, California, United States, 91016
Actively Recruiting
Research Team
G
Goel Ajay, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here